Molecular Fingerprinting in Cancer Detection

Interventions: Group 1: Study participants with cancer of the lung, prostate, bladder, breast, head and neck, liver, pancreas, ovaries, colon or with leucimia are informed in detail about the course, risks, and benefits of the study. If consent is given, 10 mL of blood will be taken. Serum and/or plasma samples will be prepared and stored.
The clinical data of the patients (e.g. age, gender, smoking status, alcohol consumption, diagnosis, treatment, concomitant medication, comorbidities and family history), as well as the results of the pathological assessment will be recorded in a central data base in pseudonymized form.
Group 2: Study participants without cancer (healthy volunteers) or patients with benign diseases of the same Organs are informed in detail about the course, risks, and benefits of the study. If consent is given, 10-20 mL of blood will be taken. Serum and/or plasma samples will be prepared and stored.
The clinical data of the patients (e.g. age, gender, smoking status, alcohol consumption, diagnosis, treatment, concomitant medication, comorbidities and family history), as well as the results of the pathological assessment (if applicable) will be recorded in a central data base in pseudonymized form.
Primary outcome(s): The primary objective of this study is the accuracy of IMF diagnosis for nine cancer entities, assessed by comparison with all data available to the investigator. A diagnoses is regarded as correct if IMF and clinical routine assessing all available data coincide with regard to the nine tumor entities of interest.
Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: diagnostic